MeiraGTx Holdings plc Asset Retirement Obligation, Period Increase (Decrease)
MeiraGTx Holdings plc (MGTX) reported Asset Retirement Obligation, Period Increase (Decrease) of $9.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Notes › Asset Retirement Obligations
us-gaap:AssetRetirementObligationPeriodIncreaseDecrease · last filed 2022-08-11
- MeiraGTx Holdings plc asset retirement obligation, period increase (decrease) for the quarter ending 2022-06-30 was -$1.00K.
- MeiraGTx Holdings plc asset retirement obligation, period increase (decrease) for the quarter ending 2022-03-31 was $10.00K.
- MeiraGTx Holdings plc asset retirement obligation, period increase (decrease) for fiscal 2021 was $120.00K.
- MeiraGTx Holdings plc asset retirement obligation, period increase (decrease) for fiscal 2019 was $1.50M.
- MeiraGTx Holdings plc asset retirement obligation, period increase (decrease) for fiscal 2018 was -$29.80K.
- MeiraGTx Holdings plc asset retirement obligation, period increase (decrease) for fiscal 2017 was -$75.01K.
| Period end | Asset Retirement Obligation, Period Increase (Decrease) 3 month | Asset Retirement Obligation, Period Increase (Decrease) 6 month | Asset Retirement Obligation, Period Increase (Decrease) 12 month |
|---|---|---|---|
| 2022-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $9.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $10.00K 10-Q · filed 2022-05-12 | ||
| 2021-12-31 | $120.00K 10-K · filed 2022-03-10 | ||
| 2019-12-31 | $1.50M 10-K · filed 2021-03-11 | ||
| 2018-12-31 | -$29.80K 10-K · filed 2020-03-11 | ||
| 2017-12-31 | -$75.01K 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |